Relay Therapeutics' GAAP loss for 3 months of 2022 was $62.046 million, up 47.1% from $42.184 million in the prior year. Revenue declined 2.3 times to $419,000 from $952,000 a year earlier.
Relay Therapeutics' GAAP loss for 3 months of 2022 was $62.046 million, up 47.1% from $42.184 million in the prior year. Revenue declined 2.3 times to $419,000 from $952,000 a year earlier. 
ir.relaytx.com
English (US) 